DDInter1293 DDInter899
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
Nilotinib {u} (Compound) binds {v} (Gene) CA7
Nilotinib {u} (Compound) upregulates {v} (Gene) HERPUD1
Nilotinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Nilotinib {u} (Compound) downregulates {v} (Gene) BNIP3
Nilotinib {u} (Compound) causes {v} (Side Effect) Lymphopenia
Nilotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Nilotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methysergide
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Nilotinib (Compound) treats hematologic cancer (Disease)
Nilotinib (Compound) binds CA7 (Gene)
Nilotinib (Compound) upregulates HERPUD1 (Gene)
Nilotinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Nilotinib (Compound) downregulates BNIP3 (Gene)
Nilotinib (Compound) causes Lymphopenia (Side Effect)
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Methysergide